COVID-19 Offerings COVID-19 Research Use Only Offerings COVID-19 Vaccine Development

COVID-19 Vaccine Development

background pattern

Simple. Powerful. Fast.
Immune System Monitoring with CyTOF

You need answers from every cell in each precious patient sample, and you need them quickly, reliably.

Mass cytometry, powered by CyTOF® technology, can expedite COVID-19 therapeutic and vaccine research studies with best-in-class, highly multiplexed, longitudinal immune monitoring capability.

Faster and more cost-efficient than single-cell RNA-seq, CITE-seq or AbSeq, mass cytometry also provides deeper resolution of immune cell phenotype and function than any flow cytometry or spectral cytometry system.

And CyTOF does it all in a single tube.

Get the flyer

Webinar: Uncovering Immunological Mechanisms of Protection from Infection and Vaccination in Humans

In this presentation, Marcelo B. Sztein, MD, shows examples of his group’s use of mass cytometry to help advance the fields of vaccine development and pathogen-host interactions. He provides an in-depth look at his studies of Salmonella typhi (S. typhi), the causative agent of typhoid fever, an infectious disease of great public health importance.

Register to watch


Presenter:

Marcelo B. Sztein, MD
Center for Vaccine Development and Global Health
University of Maryland

 

Jump-start your SARS-CoV-2 vaccine and COVID-19 therapeutic research with the Maxpar Direct Immune Profiling System.

Contact us

 

Best-in-class longitudinal immune profiling

Solves multi-site study challenges

Panel flexibility and expansion

We chose the Maxpar Direct Immune Profiling Assay for this study* because it provides a robust and standardized solution for comprehensive immune monitoring that is technically easy to execute and harmonize across multiple study sites.

– Adeeb Rahman, PhD | Icahn School of Medicine at Mount Sinai

Related Webinars

Seminar: A Complete Immune Monitoring Solution with CyTOF; Ideal for Pandemics and Beyond

Frederik De Smet, MSc, PhD, presents early data from the COVID-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) using the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software.

Watch now


Presenter:

Professor Frederik De Smet, MSc, PhD
Assistant Professor
University of Leuven, Belgium

Webinar: Profiling of COVID-19 Patient Immune Responses


Ruth Montgomery, PhD, describes her team’s work using mass cytometry in infectious disease studies and how her team will contribute to the IMPACC study by analyzing endotracheal aspirates from participants.

Watch now


Presenter:

Ruth Montgomery, PhD
Professor of Internal Medicine
Director, Yale CyTOF Facility
Associate Dean for Scientific Affairs

Clinical trials using mass cytometry in vaccine research as of September 30, 2020. 

Clinical Trial Name

Sponsor

Start Date

Phase

NCT Number

FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV University of Oxford October 2019 NA* 04222595
CVD 38000: Study of Responses to Vaccination with Typhoid and/or Cholera University of Maryland November 2018 4 03705585
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Vanderbilt-Ingram Cancer Center/ National Cancer Institute September 2016 2 02860039
Investigating Enteric Fever—Salmonella Typhi and Paratyphi Challenge Study University of Oxford, Oxford Vaccine Group December 2014 NA* 02192008
Genetic and Environmental Factors in the Response to Influenza Vaccination (SLVP028) Stanford University October 2014 1 03088904
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (SLVP030) Stanford University September 2014 1 03453801
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults University of Maryland October 2013 4 03970304
Study of a New MVA Vaccine for Hepatitis C Virus ReiThera Srl December 2010 1 01296451
Blood Donor CVD 5000 University of Maryland January 2004 4 03971669

Table 1. Clinical trials using mass cytometry to study vaccine response as of September 30, 2020. Source: clinicaltrials.gov * NA=Not applicable 

Key Publications Applying Mass Cytometry for Vaccine Research

Publications

Get more information

Unless explicitly and expressly stated otherwise, all products are provided for Research Use Only, not for use in diagnostic procedures. Find more information here.